These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 9191527

  • 1. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma.
    Li BD, Liu L, Dawson M, De Benedetti A.
    Cancer; 1997 Jun 15; 79(12):2385-90. PubMed ID: 9191527
    [Abstract] [Full Text] [Related]

  • 2. Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor.
    Sorrells DL, Meschonat C, Black D, Li BD.
    J Surg Res; 1999 Jul 15; 85(1):37-42. PubMed ID: 10383835
    [Abstract] [Full Text] [Related]

  • 3. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer.
    Wolfort R, de Benedetti A, Nuthalapaty S, Yu H, Chu QD, Li BD.
    Surgery; 2006 Aug 15; 140(2):161-9. PubMed ID: 16904965
    [Abstract] [Full Text] [Related]

  • 4. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer.
    Holm N, Byrnes K, Johnson L, Abreo F, Sehon K, Alley J, Meschonat C, Md QC, Li BD.
    Ann Surg Oncol; 2008 Nov 15; 15(11):3207-15. PubMed ID: 18719964
    [Abstract] [Full Text] [Related]

  • 5. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
    Flowers A, Chu QD, Panu L, Meschonat C, Caldito G, Lowery-Nordberg M, Li BD.
    Surgery; 2009 Aug 15; 146(2):220-6. PubMed ID: 19628077
    [Abstract] [Full Text] [Related]

  • 6. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression.
    Li BD, McDonald JC, Nassar R, De Benedetti A.
    Ann Surg; 1998 May 15; 227(5):756-6l; discussion 761-3. PubMed ID: 9605667
    [Abstract] [Full Text] [Related]

  • 7. Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome.
    Chen CN, Hsieh FJ, Cheng YM, Lee PH, Chang KJ.
    J Surg Oncol; 2004 Apr 01; 86(1):22-7. PubMed ID: 15048676
    [Abstract] [Full Text] [Related]

  • 8. Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression.
    Byrnes KW, DeBenedetti A, Holm NT, Luke J, Nunez J, Chu QD, Meschonat C, Abreo F, Johnson LW, Li BD.
    J Am Coll Surg; 2007 May 01; 204(5):925-33; discussion 933-4. PubMed ID: 17481512
    [Abstract] [Full Text] [Related]

  • 9. Detection of eIF4E gene amplification in breast cancer by competitive PCR.
    Sorrells DL, Black DR, Meschonat C, Rhoads R, De Benedetti A, Gao M, Williams BJ, Li BD.
    Ann Surg Oncol; 1998 May 01; 5(3):232-7. PubMed ID: 9607624
    [Abstract] [Full Text] [Related]

  • 10. Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma.
    Wang R, Geng J, Wang JH, Chu XY, Geng HC, Chen LB.
    Lung Cancer; 2009 Nov 01; 66(2):237-44. PubMed ID: 19261348
    [Abstract] [Full Text] [Related]

  • 11. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer.
    Salehi Z, Mashayekhi F.
    Clin Biochem; 2006 Apr 01; 39(4):404-9. PubMed ID: 16375881
    [Abstract] [Full Text] [Related]

  • 12. Predictive value of eIF4E reduction after neoadjuvant therapy in breast cancer.
    Hiller DJ, Chu Q, Meschonat C, Panu L, Burton G, Li BD.
    J Surg Res; 2009 Oct 01; 156(2):265-9. PubMed ID: 19665145
    [Abstract] [Full Text] [Related]

  • 13. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.
    Dong K, Wang R, Wang X, Lin F, Shen JJ, Gao P, Zhang HZ.
    Breast Cancer Res Treat; 2009 Feb 01; 113(3):443-56. PubMed ID: 18327707
    [Abstract] [Full Text] [Related]

  • 14. The expression of proto-oncogene eIF4E in laryngeal squamous cell carcinoma.
    Liang Z, Lei T, LuYing Z, YuPing G.
    Laryngoscope; 2003 Jul 01; 113(7):1238-43. PubMed ID: 12838026
    [Abstract] [Full Text] [Related]

  • 15. Overexpression of eukaryotic initiation factor 4E is correlated with increased risk for systemic dissemination in node-positive breast cancer patients.
    Yin X, Kim RH, Sun G, Miller JK, Li BD.
    J Am Coll Surg; 2014 Apr 01; 218(4):663-71. PubMed ID: 24491247
    [Abstract] [Full Text] [Related]

  • 16. Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas.
    Nathan CO, Carter P, Liu L, Li BD, Abreo F, Tudor A, Zimmer SG, De Benedetti A.
    Oncogene; 1997 Aug 28; 15(9):1087-94. PubMed ID: 9285563
    [Abstract] [Full Text] [Related]

  • 17. Correlation of p53 and the proto-oncogene eIF4E in larynx cancers: prognostic implications.
    Nathan CO, Sanders K, Abreo FW, Nassar R, Glass J.
    Cancer Res; 2000 Jul 01; 60(13):3599-604. PubMed ID: 10910074
    [Abstract] [Full Text] [Related]

  • 18. Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers.
    Sorrells DL, Ghali GE, De Benedetti A, Nathan CO, Li BD.
    J Oral Maxillofac Surg; 1999 Mar 01; 57(3):294-9. PubMed ID: 10077200
    [Abstract] [Full Text] [Related]

  • 19. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT, Byrnes K, Li BD, Turnage RH, Abreo F, Mathis JM, Chu QD.
    J Surg Res; 2007 Jul 01; 141(1):53-9. PubMed ID: 17574038
    [Abstract] [Full Text] [Related]

  • 20. Eukaryotic initiation factor 4E variants alter the morphology, proliferation, and colony-formation properties of MDA-MB-435 cancer cells.
    Goldson TM, Vielhauer G, Staub E, Miller S, Shim H, Hagedorn CH.
    Mol Carcinog; 2007 Jan 01; 46(1):71-84. PubMed ID: 17091471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.